Bristol-Myers Squibb’s Blenoxane (bleomycin)
Company files literature-based supplemental NDA on June 11 for the palliative treatment of malignant pleural effusion. The application consists of safety and effectiveness data from "more than 70 books, articles and published papers," BMS announces June 24. Currently, there is no FDA-approved drug for MPE. The firm says it undertook the supplemental submission in response to FDA's public comments encouraging the use of literature reviews to support approval of off-label uses. Blenoxane is approved for palliative treatment of squamous cell carcinoma, lymphomas and testicular carcinoma.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.